REITsPortfolio Plus ✦ Plus ✓
Updated on 13/07/2026

OFSA3 Ourofino Saúde Animal

Sector: Health CareSubsector: Pharma & Biotech
QuoteR$ 26,80
Dividend Yield4,81 %
P/E5,98
P/B1,77
On this page
Track OFSA3 in your portfolio

Visno Score

AI-powered fundamental analysis
Powered by AI
Final score
6.5/ 10

Rentabilidade

  • ROE médio dos últimos 5 anos: 16,2%
  • ROIC médio dos últimos 5 anos: 14,3%

Liquidez

  • Liquidez corrente: 3,46x
  • Liquidez seca: 2,38x

Alavancagem

  • Dívida Líquida / EBITDA: 0,37x
  • Dívida Líquida/Patrimônio líquido: 0,14x

Consistência

  • Número de anos consecutivos sem prejuízo: 2 anos
  • Número de anos com lucro nos últimos 10 anos: 8 anos

Crescimento

  • CAGR receita líquida 5 anos: 10,3%

Negociabilidade

  • Porcentagem de ações em circulação: 42,9%
  • Volume diário de negociações: R$ 408K/dia

Fundamental Analysis of OFSA3 (Ourofino Saúde Animal)

IA

Ourofino Saúde Animal is a company listed on B3, with shares traded under the ticker OFSA3, operating in the Healthcare sector, in the Medicines and Other Products segment. The company focuses on marketing products aimed at the animal health sector, covering both production and companion animals. Over the years, it has expanded its operations into areas such as biologicals, vaccines, and protocols related to animal production, consolidating a business model based on a diversified portfolio across the veterinary health chain.

The reported financial fundamentals indicate high profitability, with gross, net, and EBIT margins that suggest good operating efficiency for the veterinary medicines segment. Revenue and profit growth over five years points to a positive, albeit gradual, trajectory. Leverage, as measured by Net Debt/EBITDA at low levels, suggests a conservative capital structure, while current and quick liquidity indicators indicate comfort in meeting short-term obligations. These figures should be interpreted in conjunction with the cyclical and competitive profile of the animal health market.

Ourofino Saúde Animal received a 6.5 score on the Visno Score, which suggests a combination of good profitability with liquidity and leverage considered comfortable. On the other hand, the lower tradability score indicates that the trading volume of OFSA3 shares may be a point of attention for those following the stock on B3.

AI-generated analysis based on the Visno Score methodology. Data extracted from public financial statements (CVM/B3). Informational content — not investment advice.

OFSA3 Price History

Daily
one_year

OFSA3 Revenue vs. Profit

Anual

Valuation Indicators de OFSA3

Valuation Indicators for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020201920182017201620152014
Price R$ 26,80R$ 22,73R$ 16,38R$ 21,06R$ 19,33R$ 19,66R$ 28,80R$ 32,15R$ 25,04R$ 17,68R$ 20,54R$ 25,54R$ 22,14
Price/Earnings (P/E) 5,988,9610,810,0010,7512,7524,6557,5525,12387,0849,0322,730,00
Price/Book Value (P/B) 1,771,741,432,101,812,163,714,854,003,303,895,066,73
Dividend Yield 4,81 %14,57 %19,20 %2,25 %3,50 %2,41 %1,52 %0,61 %0,98 %0,63 %1,10 %1,34 %0,00 %
Price/Assets 0,890,850,801,111,001,232,052,652,191,651,942,822,81
Price/EBIT 5,516,167,0412,898,499,6022,4936,2816,7955,6528,2114,920,00
Price/Net Revenue 1,121,081,091,421,331,612,903,883,162,932,892,710,00
Price/OCF 8,1542,6115,995,9441,0020,1118,2730,7842,7114,2555,70141,130,00
Price/FCF 9,06249,2118,036,770,0029,0616,7131,5951,1510,27123,651132,920,00
EV/EBIT 5,937,607,7113,6810,0410,5824,1639,7118,9163,8232,3216,230,00
EV/EBITDA 5,176,386,1710,348,358,9218,7528,5215,3131,6222,8214,110,00
EV/Net Revenue 1,211,331,191,511,571,773,124,243,553,363,312,950,00
EV/Assets 0,951,050,871,171,191,352,202,902,471,892,233,073,17
EV/OCF 8,7752,5717,526,3148,4822,1719,6333,6948,1016,3463,82153,520,00
EV/FCF 9,75307,4719,747,180,0032,0317,9534,5757,6011,77141,681232,360,00
Book Value per Share (BVPS) R$ 15,13R$ 13,21R$ 13,51R$ 12,41R$ 13,46R$ 11,80R$ 10,23R$ 8,87R$ 8,43R$ 7,28R$ 7,19R$ 6,92R$ 4,56
Earnings per Share (EPS) R$ 4,48R$ 2,57R$ 1,79R$ -0,43R$ 2,26R$ 2,00R$ 1,54R$ 0,75R$ 1,34R$ 0,06R$ 0,57R$ 1,54R$ 0,00
Market Cap R$ 1,45 BR$ 1,24 BR$ 1,04 BR$ 1,40 BR$ 1,31 BR$ 1,38 BR$ 2,05 BR$ 2,32 BR$ 1,82 BR$ 1,29 BR$ 1,51 BR$ 1,89 BR$ 1,53 B
Enterprise Value (EV) R$ 1,56 BR$ 1,53 BR$ 1,14 BR$ 1,49 BR$ 1,55 BR$ 1,52 BR$ 2,20 BR$ 2,54 BR$ 2,05 BR$ 1,48 BR$ 1,73 BR$ 2,05 BR$ 1,73 B
Daily Volume R$ 408,19 KR$ 152,07 KR$ 125,30 KR$ 202,75 KR$ 301,99 KR$ 466,43 KR$ 575,55 KR$ 582,15 KR$ 496,07 KR$ 232,70 KR$ 269,30 KR$ 902,78 KR$ 2,78 M

Profitability Indicators de OFSA3

Profitability Indicators for OFSA3 — annual indicator history
IndicatorCurrent20252024202320222021202020192018201720162015
Gross Margin 52,58 %51,68 %50,52 %45,77 %50,72 %49,41 %51,22 %49,65 %55,01 %52,76 %49,52 %55,68 %
Net Margin 18,79 %18,15 %13,11 %—12,55 %12,59 %12,29 %7,47 %11,68 %7,54 %—12,96 %
EBIT Margin 20,41 %19,30 %18,23 %8,59 %17,03 %15,59 %13,99 %11,59 %16,63 %13,13 %1,94 %18,33 %
ROIC 19,76 %18,38 %16,74 %7,22 %15,44 %13,78 %10,69 %9,28 %13,18 %9,23 %1,28 %16,40 %
ROE 29,59 %27,90 %17,76 %—17,75 %17,77 %16,00 %9,40 %15,10 %9,39 %—18,20 %
ROA 14,82 %14,20 %9,70 %—9,70 %9,56 %8,13 %5,32 %8,14 %4,70 %—9,98 %
Asset Turnover 0,79 %0,78 %0,74 %0,74 %0,77 %0,76 %0,66 %0,71 %0,70 %0,62 %0,59 %0,77 %

Liquidity Indicators de OFSA3

Liquidity Indicators for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020201920182017201620152014
Immediate Liquidity 1,270,870,801,310,640,660,950,210,380,450,490,160,41
Current Ratio 3,463,553,063,563,252,972,852,022,421,472,662,522,07
Quick Ratio 2,382,472,152,672,001,872,051,231,521,081,741,791,58
Total Liquidity Ratio 1,461,451,501,451,471,461,391,321,261,181,111,341,31

Leverage Indicators de OFSA3

Leverage Indicators for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020201920182017201620152014
Net Debt/EBIT 0,421,010,671,581,391,571,483,292,272,8627,701,97—
Net Debt/EBITDA 0,370,870,561,091,181,311,172,451,802,087,961,63—
Net Debt/Equity 0,140,300,170,190,340,340,270,480,490,470,650,510,43
Gross Debt/Equity 0,630,610,480,630,560,600,700,570,630,770,840,570,65
Equity/Assets 0,500,510,550,540,550,540,510,570,540,500,490,550,53

Financial Results de OFSA3

Financial Results for OFSA3 — annual indicator history
IndicatorCurrent20252024202320222021202020192018201720162015
Net Revenue R$ 1,29 BR$ 1,22 BR$ 1,02 BR$ 943,28 MR$ 1,04 BR$ 904,99 MR$ 730,11 MR$ 619,59 MR$ 589,22 MR$ 505,28 MR$ 456,59 MR$ 534,04 M
Gross Profit R$ 676,10 MR$ 633,02 MR$ 517,68 MR$ 431,73 MR$ 528,08 MR$ 447,17 MR$ 373,99 MR$ 307,60 MR$ 324,13 MR$ 266,57 MR$ 226,08 MR$ 297,36 M
EBITDA R$ 301,36 MR$ 274,78 MR$ 224,51 MR$ 117,20 MR$ 209,31 MR$ 168,79 MR$ 128,51 MR$ 96,42 MR$ 123,51 MR$ 91,21 MR$ 30,78 MR$ 118,44 M
EBIT R$ 262,46 MR$ 236,47 MR$ 186,83 MR$ 81,01 MR$ 177,32 MR$ 141,11 MR$ 102,12 MR$ 71,80 MR$ 97,97 MR$ 66,35 MR$ 8,85 MR$ 97,90 M
Net Profit R$ 241,62 MR$ 222,31 MR$ 134,33 MR$ -49,98 MR$ 130,66 MR$ 113,96 MR$ 89,72 MR$ 46,28 MR$ 68,85 MR$ 38,11 MR$ -5,21 MR$ 69,19 M

Balance Sheet de OFSA3

Balance Sheet for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020201920182017201620152014
Assets R$ 1,63 BR$ 1,57 BR$ 1,38 BR$ 1,28 BR$ 1,35 BR$ 1,19 BR$ 1,10 BR$ 869,54 MR$ 846,01 MR$ 810,23 MR$ 775,58 MR$ 693,37 MR$ 627,26 M
Liabilities R$ 814,37 MR$ 768,99 MR$ 628,31 MR$ 589,63 MR$ 610,55 MR$ 551,20 MR$ 543,16 MR$ 377,09 MR$ 390,07 MR$ 404,35 MR$ 399,24 MR$ 313,19 MR$ 297,19 M
Shareholders' Equity R$ 816,47 MR$ 796,84 MR$ 756,40 MR$ 689,37 MR$ 735,95 MR$ 641,45 MR$ 560,78 MR$ 492,45 MR$ 455,94 MR$ 405,88 MR$ 376,33 MR$ 380,18 MR$ 330,07 M
Cash and Equivalents R$ 401,10 MR$ 250,82 MR$ 233,96 MR$ 304,03 MR$ 165,04 MR$ 161,25 MR$ 225,57 MR$ 45,01 MR$ 65,18 MR$ 123,36 MR$ 70,33 MR$ 23,38 MR$ 72,45 M
Inventories R$ 344,96 MR$ 312,13 MR$ 265,43 MR$ 207,89 MR$ 324,97 MR$ 270,12 MR$ 190,30 MR$ 165,29 MR$ 153,16 MR$ 108,58 MR$ 131,30 MR$ 109,26 MR$ 86,85 M
Gross Debt R$ 511,81 MR$ 489,58 MR$ 359,35 MR$ 431,97 MR$ 412,37 MR$ 382,38 MR$ 394,34 MR$ 281,08 MR$ 287,53 MR$ 313,10 MR$ 315,44 MR$ 216,49 MR$ 215,65 M
Net Debt R$ 110,71 MR$ 238,76 MR$ 125,40 MR$ 127,94 MR$ 247,33 MR$ 221,12 MR$ 150,72 MR$ 236,07 MR$ 222,35 MR$ 189,74 MR$ 245,11 MR$ 193,11 MR$ 143,20 M
Short-Term Debt R$ 57,92 MR$ 52,14 MR$ 56,89 MR$ 98,85 MR$ 88,23 MR$ 85,05 MR$ 96,55 MR$ 118,23 MR$ 76,44 MR$ 190,23 MR$ 73,55 MR$ 57,26 MR$ 103,09 M
Long-Term Debt R$ 453,90 MR$ 437,44 MR$ 302,46 MR$ 333,12 MR$ 324,14 MR$ 297,33 MR$ 297,79 MR$ 162,85 MR$ 211,09 MR$ 122,87 MR$ 241,89 MR$ 159,23 MR$ 112,56 M

Cash Flow de OFSA3

Cash Flow for OFSA3 — annual indicator history
IndicatorCurrent20252024202320222021202020192018201720162015
OCF R$ 177,51 MR$ 99,91 MR$ 73,94 MR$ 190,30 MR$ 89,59 MR$ 46,50 MR$ 111,94 MR$ 56,39 MR$ 42,81 MR$ 99,50 MR$ 42,20 MR$ 15,51 M
ICF R$ -35,56 MR$ -41,77 MR$ -42,88 MR$ -37,14 MR$ -78,15 MR$ -60,41 MR$ -23,53 MR$ -50,40 MR$ -46,41 MR$ -25,24 MR$ -86,82 MR$ -56,00 M
Financing CF R$ 111,25 MR$ -40,65 MR$ -102,17 MR$ -14,36 MR$ -7,95 MR$ -50,62 MR$ 91,52 MR$ -26,30 MR$ -54,77 MR$ -21,22 MR$ 92,76 MR$ -8,76 M
CAPEX R$ -17,85 MR$ -24,39 MR$ -17,03 MR$ -14,88 MR$ -45,41 MR$ -50,13 MR$ 998,00 KR$ 1,73 MR$ 1,92 MR$ 6,61 MR$ 1,28 MR$ 1,06 M
FCF R$ 159,65 MR$ 75,52 MR$ 56,91 MR$ 175,42 MR$ 44,17 MR$ -3,63 MR$ 112,93 MR$ 58,12 MR$ 44,73 MR$ 106,11 MR$ 43,48 MR$ 16,57 M

Growth de OFSA3

Growth for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020
Net Revenue CAGR 5Y 10,32 %10,90 %10,59 %9,87 %15,56 %14,66 %6,45 %
Net Profit CAGR 5Y 18,97 %19,90 %23,75 %—27,95 %—5,33 %
EBIT CAGR 5Y 16,90 %18,29 %21,08 %-3,73 %21,73 %73,99 %0,85 %
EBITDA CAGR 5Y 15,49 %16,41 %18,42 %-1,04 %18,07 %40,55 %1,65 %

Target Price de OFSA3

Target Price for OFSA3 — annual indicator history
IndicatorCurrent202520242023202220212020201920182017201620152014
Target Price - Graham R$ 39,05R$ 27,62R$ 23,33R$ 0,00R$ 26,17R$ 23,04R$ 18,84R$ 12,21R$ 15,95R$ 3,19R$ 9,61R$ 15,48R$ 0,00

Registration Data de OFSA3

Registration Data for OFSA3 — annual indicator history
Sector Health Care
Subsector Pharma & Biotech
Website www.ri.ourofino.com
Status Fase Operacional
Years Listed 11
CVM Code 23507
CNPJ 20.258.278/0001-70
Last Price Date 13/07/2026
Last Earnings Date 31/03/2026
Next Earnings Date 06/08/2026
Free Float 42,94 %
Other Tickers N/A

About Ourofino Saúde Animal

Ourofino S.A., known in the market as Ourofino Saúde Animal, is a Brazilian company dedicated to the animal health sector, with common shares traded on B3 under the ticker OFSA3. The economic group originated in 1987, founded by Norival Bonamichi and Jardel Massari, with an initial focus on manufacturing veterinary products for production animals, especially cattle, horses, poultry, and swine. Throughout the 1990s, expansion occurred organically, supported mainly by its livestock product line. In 2000, the company began diversifying by entering the market for companion animal products, covering dogs and cats, broadening the scope of its portfolio and customer base. Between 2001 and 2004, the company invested in building an industrial and technology complex in Cravinhos, in the state of São Paulo, to accommodate the growth of operations and incorporate more modern production and research infrastructure.

Ourofino Saúde Animal’s technological development trajectory reached an important milestone in 2007, with the start of investments in the biologicals area, including construction of a biosafe industrial plant for the production of foot-and-mouth disease vaccines. Biosafety certification from the Ministry of Agriculture and Livestock (MAPA) was obtained in 2008, allowing the receipt of viral seeds and the development of the vaccine, which was authorized for sale in 2010. In the same period, the company structured an industrial unit dedicated to hormonal therapeutic products, aiming to offer a complete protocol for fixed-time artificial insemination (FTAI), with in-house manufacturing starting in 2008. In 2014, the company completed its initial public offering and its shares began trading on B3’s Novo Mercado segment, reinforcing its corporate governance framework. From 2015 onward, the company intensified its international strategy, strengthening its presence in Mexico and acquiring its local distributor in Colombia, consolidating a growth platform in Latin America.

Ourofino Saúde Animal’s business model is centered on manufacturing and marketing vaccines and veterinary products, with a focus on three main fronts: production animals, companion animals, and international operations. In the production animal segment, the company develops and sells vaccines and veterinary specialties for ruminants, poultry, swine, and horses, in addition to providing contract manufacturing services for third parties. This segment accounts for most of the net operating revenue, representing 72.1% of revenue in 2024, highlighting the company’s strong link to agribusiness and the animal protein chain. In companion animals, the company manufactures and sells products for dogs and cats, including otological, dermatological, nutritional, antibiotic, anti-inflammatory, analgesic, antiparasitic lines, rapid diagnostic kits, and disinfectants. International operations include the production and export of vaccines and veterinary products for production animals and pets, with a presence in 14 countries and particular strategic relevance in Mexico and Colombia.

The company structures its operating segments based on the nature of its customers and the usage profile of its products. In production animals, it serves more than 3,900 active customers in Brazil, including agricultural retailers, cooperatives, agribusinesses, distributors, and large livestock producers, with a portfolio of 120 SKUs in 2024 that includes vaccines, antiparasitics, antibiotics, therapeutics, and nutritional products. In the companion animal segment, distribution is organized into 36 operating areas, reaching more than 30,000 points of sale in the country, with 102 SKUs of veterinary products for dogs and cats. Portfolio diversification includes recombinant vaccines and diagnostic solutions, such as the Conclue line of rapid tests for canine and feline diseases, as well as products like the insecticidal ear tag Na Mosca and the rabies vaccine Ourovac Raiva for herds. Revenue from international operations, which accounted for 12.6% of net operating revenue in 2024, complements the company’s positioning as a regional provider of animal health solutions.

Ourofino Saúde Animal’s geographic footprint is anchored in its industrial complex in Cravinhos, São Paulo, which concentrates biological and pharmaceutical plants, including biotechnology, hormonal therapeutics, injectables, oral liquids, solids, creams, ointments, and animal protection products. The company operates a decentralized logistics network in Brazil, based on leased distribution centers in Vinhedo (SP), Cachoeirinha (RS), Aparecida de Goiânia (GO), Betim (MG), and Cuiabá (MT). These centers are supplied from the factory according to demand forecasts, which helps shorten delivery times, increase capillarity, and maintain service levels compatible with the national reach of its customers. In addition, the company keeps part of its inventory at its industrial plant as a strategic supply reserve, reinforcing its ability to respond to potential disruptions. Abroad, its strategy focuses on expansion in Latin American markets with significant animal protein production, with commercial and distribution focus especially in Mexico and Colombia.

Research, development, and innovation are a core pillar of Ourofino Saúde Animal’s operations. The company maintains an RDI structure that integrates new business, open innovation, regulatory affairs, project management, research and development, and finance, with formal processes for ideation, prototyping, advanced development, pre-clinical studies, clinical trials, and product registration. The R&D team is made up of professionals from different backgrounds, such as pharmacists, veterinarians, chemists, biologists, and biotechnologists. The company adopts an open innovation model, with partnerships with universities, research centers, and national and international experts, and conducts studies on cattle and swine at an experimental farm located in Guatapará, also in the state of São Paulo. The managerial separation between research and development of drugs and of biologicals seeks to broaden focus and performance in developing new solutions and improving existing formulations.

Ourofino Saúde Animal’s activities take place in a highly regulated environment. The manufacturing, quality control, marketing, storage, import, and export of veterinary and animal feed products depend on registration and licenses with the Ministry of Agriculture and Livestock, through the Agricultural Defense Secretariat. Industrial facilities and products must comply with Good Manufacturing Practices standards, biosafety regulations, hygiene and occupational safety rules, with licenses renewed periodically. Veterinary products, including vaccines, are registered with MAPA’s Veterinary Products Registration Coordination, with defined expiration and renewal periods. The company is also subject to requirements from the Regional Council of Veterinary Medicine, including the need for a registered technical manager, and to rules applicable to substances subject to special control, supervised by the Army, Federal Police, and Civil Police. Additionally, research activities involving genetically modified organisms must comply with the Biosafety Law and obtain authorization from CTNBio, with oversight by the Internal Biosafety Commission, while the use of animals in research is monitored by ethics committees and by the National Council for the Control of Animal Experimentation.

In environmental, social, and governance practices, Ourofino Saúde Animal has begun to guide its strategy using materiality matrices and objectives linked to the Sustainable Development Goals, maintaining its commitment to the United Nations Global Compact since 2019. The company has set up a Sustainability Committee with members specialized in the topic, with the goal of integrating environmental, social, and governance considerations into business decisions and risk management. In recent years, it has also promoted adjustments to its organizational culture, with corporate values that include performance focus, care for people, and connection with the external environment. The evolution of ESG initiatives, combined with the company’s relevance in the animal health market and the trading of OFSA3 shares on B3, places Ourofino Saúde Animal in a context of greater transparency, public monitoring, and alignment with more formalized governance practices in the Brazilian capital market.

OFSA3 Dividend History

Latest dividends paid by OFSA3 — Dividends and Interest on Equity (JCP)
TypeEx-DateValue per Share
Dividendo16/04/2026R$ 0,36
JCP23/12/2025R$ 0,93
Dividendo17/04/2025R$ 0,15
Restituição30/12/2024R$ 2,23
JCP20/12/2024R$ 0,58
Dividendo29/04/2024R$ 0,34
JCP19/12/2023R$ 0,28
Dividendo14/04/2023R$ 0,20
JCP16/12/2022R$ 0,44
Dividendo20/04/2022R$ 0,24
JCP17/12/2021R$ 0,30
Dividendo09/04/2021R$ 0,17
JCP23/12/2020R$ 0,25
Dividendo14/10/2020R$ 0,19
JCP19/12/2019R$ 0,02
Dividendo29/03/2019R$ 0,18
JCP14/12/2018R$ 0,14
Dividendo13/04/2018R$ 0,10
JCP19/12/2017R$ 0,11
Dividendo29/04/2016R$ 0,22
JCP21/12/2015R$ 0,09
Dividendo28/04/2015R$ 0,18
JCP02/01/2015R$ 0,07

Find new opportunities

Discover stocks with the best fundamentals

Open Screener

Latest News on OFSA3

About Ourofino Saúde Animal

No news found

OFSA3 indicator guide

What is OFSA3's current price?

What is OFSA3's Price today?

OFSA3's Price is R$ 26,80 (13/07/2026).

What is Price and what does it indicate?

The stock's latest market price, representing the value at which it traded at the most recent close.

How should OFSA3's Price be interpreted?

Price changes reflect shifts in market expectations; monitoring them alongside other indicators helps identify opportunities and risks.

What can affect OFSA3's Price?

It is influenced by the company's financial performance, market news, macroeconomic conditions, and investor sentiment.

OFSA3's P/E: is the stock expensive or cheap?

What is OFSA3's Price/Earnings (P/E) today?

OFSA3's Price/Earnings (P/E) is 5,98 (13/07/2026).

What is Price/Earnings (P/E) and what does it indicate?

Price/Earnings relates the stock's market price to earnings per share, showing how much investors are willing to pay for the company's earnings.

How should OFSA3's Price/Earnings (P/E) be interpreted?

A high P/E generally suggests strong expectations for future growth, while a low P/E may indicate an undervalued stock or operating challenges.

What can affect OFSA3's Price/Earnings (P/E)?

This indicator is influenced by operating results, earnings growth, macroeconomic conditions, and investor expectations, and varies across the economic cycle.

OFSA3's P/B: what it reveals about valuation

What is OFSA3's Price/Book Value (P/B) today?

OFSA3's Price/Book Value (P/B) is 1,77 (13/07/2026).

What is Price/Book Value (P/B) and what does it indicate?

Price/Book Value per Share relates the stock's market price to book value per share, showing how much investors pay for the company's equity.

How should OFSA3's Price/Book Value (P/B) be interpreted?

A P/B below 1 may signal an undervalued stock, while a high value may reflect expectations of future appreciation or risks related to asset quality.

What can affect OFSA3's Price/Book Value (P/B)?

Capital structure, the share of intangible assets, reinvestment policies, and economic conditions significantly affect book value.

OFSA3's Dividend Yield: how much does it pay in dividends?

What is OFSA3's Dividend Yield today?

OFSA3's Dividend Yield is 4,81 % (13/07/2026).

What is Dividend Yield and what does it indicate?

Dividend Yield is the percentage relationship between dividends paid to shareholders and the current stock price, showing the return received as dividends.

How should OFSA3's Dividend Yield be interpreted?

A high Dividend Yield may indicate an income opportunity, but it should be assessed alongside earnings stability and the consistency of dividend distributions over time.

What can affect OFSA3's Dividend Yield?

The company's dividend policy, financial results, cash flow, and capital allocation strategies are key drivers of Dividend Yield.

OFSA3's EV/EBITDA: valuation accounting for debt

What is OFSA3's EV/EBITDA today?

OFSA3's EV/EBITDA is 5,17 (13/07/2026).

What is EV/EBITDA and what does it indicate?

EV/EBITDA relates enterprise value to EBITDA, highlighting operating cash-generation capacity before depreciation and amortization.

How should OFSA3's EV/EBITDA be interpreted?

A low value may suggest an attractive valuation, while a high value may indicate an expensive valuation or weak operating cash generation.

What can affect OFSA3's EV/EBITDA?

Depreciation policies, investments, and operating efficiency influence EBITDA.

OFSA3's BVPS: what is the book value per share?

What is OFSA3's Book Value per Share (BVPS) today?

OFSA3's Book Value per Share (BVPS) is R$ 15,13 (13/07/2026).

What is Book Value per Share (BVPS) and what does it indicate?

Book Value per Share is the accounting value assigned to each share, reflecting the company's equity on a per-share basis.

How should OFSA3's Book Value per Share (BVPS) be interpreted?

A low Book Value per Share may indicate an undervalued stock, while a high value may suggest the stock is expensive on an accounting basis.

What can affect OFSA3's Book Value per Share (BVPS)?

Asset revaluations, retained earnings, and dividend policies influence Book Value per Share.

OFSA3's EPS: how much profit per share?

What is OFSA3's Earnings per Share (EPS) today?

OFSA3's Earnings per Share (EPS) is R$ 4,48 (13/07/2026).

What is Earnings per Share (EPS) and what does it indicate?

Earnings per Share is net income divided by the total number of shares, indicating the earnings attributable to each share.

How should OFSA3's Earnings per Share (EPS) be interpreted?

Rising Earnings per Share is a positive profitability signal, while a decline may indicate challenges in generating earnings.

What can affect OFSA3's Earnings per Share (EPS)?

Operating efficiency, cost management, and changes in net income influence Earnings per Share.

OFSA3's Market Cap: how much is the company worth on the exchange?

What is OFSA3's Market Cap today?

OFSA3's Market Cap is R$ 1,45 B (13/07/2026).

What is Market Cap and what does it indicate?

Market capitalization is the company's total market value, calculated by multiplying the share price by the number of shares outstanding.

How should OFSA3's Market Cap be interpreted?

A high market capitalization may indicate an established company, while a low value may point to growth opportunities or greater volatility.

What can affect OFSA3's Market Cap?

Share price, share count, and market conditions influence market capitalization.

OFSA3's Net Margin: how much profit is left per dollar sold?

What is OFSA3's Net Margin today?

OFSA3's Net Margin is 18,79 % (13/07/2026).

What is Net Margin and what does it indicate?

Net Margin is net income as a percentage of net revenue, showing the company's effective profitability.

How should OFSA3's Net Margin be interpreted?

High margins indicate efficient conversion of revenue into profit, while low margins may signal challenges.

What can affect OFSA3's Net Margin?

Cost management, operating expenses, and the tax burden influence Net Margin.

OFSA3's ROIC: the return on invested capital

What is OFSA3's ROIC today?

OFSA3's ROIC is 19,76 % (13/07/2026).

What is ROIC and what does it indicate?

ROIC (Return on Invested Capital) measures the return earned on all capital invested in the company, reflecting how efficiently resources are used.

How should OFSA3's ROIC be interpreted?

A high ROIC suggests efficient use of resources, while a low ROIC may indicate inefficient capital allocation.

What can affect OFSA3's ROIC?

Investment strategies, operating efficiency, and capital structure influence ROIC.

OFSA3's ROE: is the company efficient at generating profit?

What is OFSA3's ROE today?

OFSA3's ROE is 29,59 % (13/07/2026).

What is ROE and what does it indicate?

ROE (Return on Equity) measures the return on shareholders' equity, reflecting profitability for shareholders.

How should OFSA3's ROE be interpreted?

A high ROE is generally positive, but it should be assessed together with the company's capital structure.

What can affect OFSA3's ROE?

Operating management, dividend policy, and financial leverage influence ROE.

OFSA3's Net Debt/EBITDA: is the debt level healthy?

What is OFSA3's Net Debt/EBITDA today?

OFSA3's Net Debt/EBITDA is 0,37 (13/07/2026).

What is Net Debt/EBITDA and what does it indicate?

Net Debt/EBITDA assesses the company's ability to repay debt with cash generated by operations, before depreciation and amortization.

How should OFSA3's Net Debt/EBITDA be interpreted?

Low values indicate greater financial safety, while high values may signal excessive debt risk.

What can affect OFSA3's Net Debt/EBITDA?

Capital structure, operating efficiency, and investments influence EBITDA.

Stocks Related to OFSA3

Companies in the same sector on B3
HYPE3Hypera
QuoteR$ 20,77
DY5,35 %
P/E8,69
Pharma & Biotech
BIOM3Biomm
QuoteR$ 6,26
DY0,00 %
P/E35,61
Pharma & Biotech
BLAU3Blau Farmacêutica
QuoteR$ 10,30
DY7,23 %
P/E9,85
Pharma & Biotech
RDOR3Rede D'Or São Luiz
QuoteR$ 35,56
DY11,95 %
P/E17,64
Health Care
RADL3RaiaDrogasil
QuoteR$ 18,20
DY1,78 %
P/E24,69
Health Care
HAPV3Hapvida
QuoteR$ 10,46
DY0,00 %
P/EN/A
Health Care
SAUD3Odontoprev
QuoteR$ 15,25
DY3,82 %
P/E14,73
Health Care
FLRY3Fleury
QuoteR$ 16,15
DY7,49 %
P/E13,92
Health Care

Frequently Asked Questions about OFSA3

What is OFSA3's stock price today?

OFSA3's price on 13/07/2026 is R$ 26.80. The price is updated based on the latest data available from B3.

Does OFSA3 pay dividends?

Over the last 12 months, OFSA3 paid dividends and/or JCP in April, and December, totaling R$ 1.29 per share (Dividend Yield of 4.81%). Payments depend on results and decisions made by the board of directors.

How do I buy OFSA3 shares?

To buy OFSA3 (Ourofino Saúde Animal) shares, you need an account with a brokerage that has access to B3. After that, just search for the ticker OFSA3 and place a buy order through the brokerage's platform.

How do I analyze OFSA3 stock?

To analyze OFSA3, consider indicators such as P/E of 5.98, Dividend Yield of 4.81%, ROE of 29.59%, net margin of 18.79%. The evaluation should include comparison with companies in the same sector and the company's financial history.